A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. - Wikidata - awgldk - TriplyDB

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.

http://www.wikidata.org/entity/Q34476154

about

Beta-thalassemia Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia Deferasirox for managing iron overload in people with myelodysplastic syndrome Deferasirox for managing transfusional iron overload in people with sickle cell disease Deferasirox for managing iron overload in people with thalassaemia Deferasirox for managing transfusional iron overload in people with sickle cell disease Deferasirox for managing iron overload in people with myelodysplastic syndrome Deferasirox for managing iron overload in people with thalassaemia Deferasirox for managing iron overload in patients with myelodysplastic syndrome Deferasirox for managing transfusional iron overload in people with sickle cell disease Oral deferiprone for iron chelation in people with thalassaemia HLA-matched sibling bone marrow transplantation for β-thalassemia major Recent advances in the management of mucormycosis: from bench to bedside Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectives Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions Pharmacology of iron transport Guidelines on haemovigilance of post-transfusional iron overload Transferrin-mediated iron sequestration as a novel therapy for bacterial and fungal infections Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases Pharmacogenetic study of deferasirox, an iron chelating agent Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months.Safety and efficacy of deferasirox in multitransfused Indian children with β-thalassaemia major.Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.Antiproliferative effect on HepaRG cell cultures of new calix[4]arenes. Part II.Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major.Liver iron content determination by magnetic resonance imaging.Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan.Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.Quality of life in patients with thalassemia major.Advances in iron chelation therapy: transitioning to a new oral formulation.Transferrin iron starvation therapy for lethal bacterial and fungal infections.Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload.Cardiac iron across different transfusion-dependent diseases.Iron chelation therapy in myelodysplastic syndromes.Recent advances in the treatment of mucormycosis.Recent advances in treatment of aplastic anemia.Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis Iron-chelating therapy for transfusional iron overload

P2860

Q21202886-9F5566E3-136A-4F69-B2D7-C45A3E042DF8 Q24186957-211ADCCF-1540-4BD1-AE42-211F23856370 Q24193067-CE320FF5-1BA9-47CE-B767-2D8913CA68E1 Q24194549-B2B0F000-C3BC-4478-8782-4104402AC954 Q24203718-7D9D3FF8-9A2C-4BCB-88E4-84D6A104B680 Q24236463-F912A120-2E5E-4302-8C37-CB3630199F5E Q24236532-09DD280D-BCBE-46D9-8308-2AAD8177528A Q24241753-0B58916A-3BD5-4DE1-95BC-D5D283D5E4FF Q24242437-3B88F4D4-0139-45AC-9FCE-618A14A54C63 Q24242535-CCEF4030-8B7B-4DFF-B938-31CEC8AB2716 Q24244045-9002F2CA-0DA6-4D51-921D-1737B484023A Q24600037-3D02358B-1A47-442E-8E9F-E86DADD2BCEC Q24642450-12875380-EC0C-4180-B98D-49EADDCAC641 Q26740347-AC127064-86A9-49DC-AE89-CCBF96615C4F Q26765306-A66DFB70-088F-47D9-BF82-A27F9E946953 Q27009387-8A5C8221-82BB-4CD3-8D00-84C70633F153 Q27022721-9E7436C4-4C61-4570-9FFF-AFF6E6316FEA Q28084708-7EDA4AE7-8E5C-4782-A9A7-FE1198DD32F6 Q28388335-62A9EA2B-DFA7-44B1-8774-0E176F5B8AA0 Q28533457-C712B0CB-37BF-4C09-AB2C-F84C5C9B6432 Q31037298-5E741677-B6CC-4197-87C9-06942AD5E0CE Q33392822-75F3D3C9-D656-4513-91A9-68FFBBC937CE Q33393791-05C3F62D-5437-42D1-82B1-20737AD0AB17 Q33411923-96C5BE0E-59F9-4565-B575-3286972E021A Q33603341-16BF34D9-A5F1-40C4-A7F1-F5FAFA118FF5 Q33670385-52C16BA0-AF31-452E-AC4C-0FFE608AB53C Q33764777-7B346A9F-89FC-4B85-B6E0-F520F978764D Q33783224-7DB9BF01-ECCB-4998-9198-872E17BBB657 Q33801826-0B6A66D7-298B-4509-BE8B-FEC3CF81F01A Q33850985-28F26C33-8CE8-41BE-9869-8A929E18C730 Q33879123-7252CA51-DC38-4B2D-9397-149C82FA8419 Q33883214-18D2AFD1-2918-4675-B3F2-5E874CE29B1A Q33909024-86E27780-C0ED-4E55-B489-448AB3071F50 Q33958560-8119F35A-E7D4-41A9-8EE0-1D05970E98F0 Q34002840-0EA1C15E-61AB-497F-9EAE-FB38718111CC Q34161213-B49DFC47-2696-4181-97DB-3A9CF7E7E703 Q34451351-4B34F80E-3151-42CD-9768-024AAC7A9771 Q34451519-F93EA74D-5A95-4D25-ACEA-0DCA2EB03561 Q34553682-B555D50E-F985-4801-B2C9-5EBEE5FA3753 Q34806460-FC9CAB1E-6041-4BB6-96C2-8624278208D3

P2860

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.

http://www.wikidata.org/entity/Q34476154

description

2005 nî lūn-bûn

@nan

2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

A phase 3 study of deferasirox ...... atients with beta-thalassemia.

@ast

A phase 3 study of deferasirox ...... atients with beta-thalassemia.

@en

A phase 3 study of deferasirox ...... atients with beta-thalassemia.

@nl

type

label

A phase 3 study of deferasirox ...... atients with beta-thalassemia.

@ast

A phase 3 study of deferasirox ...... atients with beta-thalassemia.

@en

A phase 3 study of deferasirox ...... atients with beta-thalassemia.

@nl

prefLabel

A phase 3 study of deferasirox ...... atients with beta-thalassemia.

@ast

A phase 3 study of deferasirox ...... atients with beta-thalassemia.

@en

A phase 3 study of deferasirox ...... atients with beta-thalassemia.

@nl

P1433

Q34476154-5AC4A2AF-0675-4F99-9347-04B9056B93CA

P1476

Q34476154-335D1083-EE50-49AD-8585-F4BEEB1C7BE4

P2093

Q34476154-004C09B3-4B65-4EE0-B990-00DB9838CD6D

Q34476154-01FDD2A0-48C2-4467-8EF4-E2D7B7E0D4C0

Q34476154-0A07DD62-5784-4376-BD60-8E9513D41C83

Q34476154-1117E252-E043-410E-825A-02B59DA6F917

Q34476154-16E99907-BE83-4296-9DB6-AED745F2E541

Q34476154-2C2B3682-A0BA-4F60-A62C-B5288B658201

Q34476154-2E70138D-6E61-4FD4-B679-DACD3C6A1473

Q34476154-3B5B62E0-6FA8-473B-8CBB-AA9E52C8C2AF

Q34476154-3C9B6ABC-0764-4B20-BC2E-4E077B444264

Q34476154-40D9EE90-0EDE-4BFF-BBC6-8A668F48D72B

P304

Q34476154-4170C3F0-B581-40F5-B40E-C3091220B960

P31

Q34476154-F06456A2-DE99-4C83-BFB2-A569E5BE6036

P356

Q34476154-EAB798C4-5103-442B-AAFE-9E44B50E1216

P407

Q34476154-5B09DB1A-1927-40AB-821F-1194F873A3DE

P433

Q34476154-F6781CE5-042F-44AA-8616-5BCE0FC69F04

P478

Q34476154-E3F1A83F-8BA5-4428-9D27-A80F23BDF1D0

P577

Q34476154-230E223E-B245-4F22-90C1-0A30C76A405E

P5875

Q34476154-6640C4A9-E7B6-44E7-9609-BF8AFD5EBDFF

P698

Q34476154-09F8378E-8940-4F68-B3AF-8E6D64A19D81

P356

BLOOD-2005-08-3430

P1433

P1476

A phase 3 study of deferasirox ...... atients with beta-thalassemia.

@en

P2093

Alan Cohen

http://www.w3.org/2001/XMLSchema#string

Alexandra Kourakli-Symeonidis

http://www.w3.org/2001/XMLSchema#string

Antonio Piga

http://www.w3.org/2001/XMLSchema#string

Antonis Kattamis

http://www.w3.org/2001/XMLSchema#string

Carmelo Magnano

http://www.w3.org/2001/XMLSchema#string

Catherine Ressayre-Djaffer

http://www.w3.org/2001/XMLSchema#string

Christiane Vermylen

http://www.w3.org/2001/XMLSchema#string

Daniele Alberti

http://www.w3.org/2001/XMLSchema#string

Gritta Janka-Schaub

http://www.w3.org/2001/XMLSchema#string

Guillermo Drelichman

http://www.w3.org/2001/XMLSchema#string

P304

3455-3462

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2005-08-3430

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P577

2005-12-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7416843

http://www.w3.org/2001/XMLSchema#string

P698

16352812

http://www.w3.org/2001/XMLSchema#string